SVB Securities analyst Jonathan Chang reiterated a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) on November 8 and set a price target of $3.00. The company’s shares closed yesterday at $2.10.
Chang covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Adaptimmune Therapeutics, and Immatics. According to TipRanks, Chang has an average return of -14.4% and a 24.72% success rate on recommended stocks.
Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.70, a 171.43% upside from current levels. In a report released on October 25, Mizuho Securities also maintained a Hold rating on the stock with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ADAP market cap is currently $339.8M and has a P/E ratio of -1.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
